LGS

Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Retrieved on: 
Monday, May 6, 2024
Technology, Health, Venture Capital, Professional Services, Artificial Intelligence, Oncology, Other Science, Mental Health, Research, Software, Health Technology, Science, COVID-19, Clinical Trials, Komodo, University of Washington, Lennox–Gastaut syndrome, FDA, Public, University, Target, International Society, RWE, Pregnancy, Policy, AI, Prevalence, Colorectal cancer, Myriad Genetics, LGS, Chronic inflammatory demyelinating polyneuropathy, Neutropenia, CRC, Conference, Workflow, REMS, Genetics, Schizophrenia, Takeda Pharmaceutical Company, Mental health, Neurology, RWD, MPH, Patient, Hypertension, Epilepsy, Gestational age, Standard of care, Stillbirth, Pharmacoeconomics, ZS, Merck, ZS Associates, Breast cancer, Mitigation, Pharmaceutical industry

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.

Key Points: 
  • Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.
  • The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
  • Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
  • Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.

Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Genetics, Health, Factorization of polynomials, Lennox–Gastaut syndrome, Brain, DRG, DSM-IV codes, SCN9A, Dorsal root ganglion, Dravet syndrome, ETF, Central nervous system disease, Gene silencing, LGS, Transgene, Neuroscience, Abstract, Code, CNS, GABAergic, Engineering, Res, Interneuron, MAPT, Angelman syndrome, Neuropathic pain, Central nervous system, Therapy, MicroRNA, Vaccine

Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.

Key Points: 
  • Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.
  • “Our ASGCT presentations showcase the depth and versatility of our vector engineering platform to develop highly specific precision therapies for CNS disorders with high unmet need,” said Stephanie Tagliatela, Chief Scientific Officer at Encoded.
  • “Combining our novel regulatory elements and transgenes provides control of expression in target cells, potentially enabling treatment of devastating, intractable diseases.
  • Engineered transgenes include transcription factors (eTFs) that upregulate the expression of endogenous genes as well miRNA sequences derived from Encoded’s miRNA discovery platform.

Lennox-Gastaut Syndrome (LGS) Foundation Announces Exciting New Research Funded in Time for the 9th Annual Walk 'n' Wheel for LGS Research

Retrieved on: 
Tuesday, April 16, 2024
Research program, Weill Cornell Medical Center, Hope, Risk, Research, LGS, Lennox–Gastaut syndrome, Friends, DRS, Walking, SAN

SAN DIEGO, April 16, 2024 /PRNewswire/ -- On April 20, 2024, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 9th Annual Walk 'n' Wheel for LGS Research.

Key Points: 
  • SAN DIEGO, April 16, 2024 /PRNewswire/ -- On April 20, 2024, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 9th Annual Walk 'n' Wheel for LGS Research.
  • Lennox-Gastaut Syndrome (LGS) is a rare, severe, life-threatening epilepsy syndrome that develops in children and leads to lifelong disability.
  • A critical part of this Research Program is funding patient-led research by awarding Cure LGS 365 Research Grants.
  • The LGS Foundation recently funded an exciting new research study conducted by Drs.

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Medication, Seizure, Standard of care, LGS, DEE, DS, Safety, SAD, FDA, DSM-IV codes, Pharmaceutical industry

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.
  • “I am extremely proud of what our team has accomplished starting with the immense effort that went into the PACIFIC Study in participants with DEEs.
  • We appreciate the tremendous support from our existing and new shareholders who play an integral part in the continued success of Longboard.
  • Of note, results were on top of current standard of care; participants were typically on 3-4 other anti-seizure medications.

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024
Graviton, Epilepsy, Pharmacy technician, CCM, Research, Transcranial magnetic stimulation, DS, Neuron, Vigabatrin, LGS, Psychosis, Biomarker, Element, Ligand Pharmaceuticals, Lennox–Gastaut syndrome, Patient, Acceleration, Medicine, Status epilepticus, Dravet syndrome, ROCK2, KCC2, Hemangioma, IND, Seizure, Pharmaceutical industry

In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.

Key Points: 
  • In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
  • Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023.
  • Financial runway: Ovid anticipates its cash runway will support operations and clinical development programs into the first half of 2026.
  • Ovid also anticipates several events for its current pipeline programs and clinical results for soticlestat from Takeda in 2024.

Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

Retrieved on: 
Tuesday, February 13, 2024
Health authority, Altea, TSX, SAS, GMP, Dravet syndrome, LGS, Patient, CBD, Lennox–Gastaut syndrome, Cannabidiol, Seizure, Pharmaceutical industry

“The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.

Key Points: 
  • “The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.
  • It is also rewarding to be able to deliver this medication for such a critical medical condition at an accessible price through our vertical,” stated Aras Azadian, CEO.
  • The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
  • Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two of the various, rare epileptic disorders classified as epileptic encephalopathies.

GN Fully Hydraulic Drive Centrifuge Improve Solids Control for Offshore Drilling Mud

Retrieved on: 
Saturday, February 10, 2024
Compact, Torque, Risk, HGS, Research, LGS, Renewable energy

HOUSTON and TANGSHAN, China, Feb. 9, 2024 /PRNewswire-PRWeb/ -- GN Solids Control, a pioneering force in separation technology, has unveiled its latest innovation: the GN Fully Hydraulic Drive Centrifuge. Engineered with precision for offshore drilling mud applications, this cutting-edge centrifuge marks a significant advancement in industrial separation, setting new standards in solids control for offshore drilling operations.

Key Points: 
  • GN Solids Control introduces the GN Fully Hydraulic Drive Centrifuge, revolutionizing offshore drilling mud solids control.
  • HOUSTON and TANGSHAN, China, Feb. 9, 2024 /PRNewswire-PRWeb/ -- GN Solids Control , a pioneering force in separation technology, has unveiled its latest innovation: the GN Fully Hydraulic Drive Centrifuge.
  • With a steadfast commitment to innovation, GN Solids Control is poised to shape the future of drilling mud solid control decanter centrifuge solutions in the offshore drilling industry.
  • For more information about the GN Fully Hydraulic Drive Centrifuge and other groundbreaking solutions, visit GN Solids Control's official website .

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Diarrhea, DSM-IV codes, Cannabidiol, Lethargy, Partnership, Constipation, Clobazam, Aes, Lamotrigine, Caregiver, Principal, Research, LGS, TID, DEE, ASMS, Medication, Data, Physician, Somnolence, MD, Doctor of Philosophy, DS, SAE, Seizure, Combination, Pharmacokinetics, Appetite, Participation, Patient, Diagnosis, Safety, Levetiracetam, MSCE, Pharmaceutical industry

Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).

Key Points: 
  • Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).
  • The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group.
  • Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg).
  • 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

AXSM FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

Retrieved on: 
Friday, November 24, 2023
Titan, Food, Class, LGS, CMC, Person, Court, NDA, Therapy, New Drug Application, Class Action, Plaintiff, Advertising, District court

WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Friday, December 1, 2023
Responsive neurostimulation device, Epilepsy, Generalization, LGS, AES, Hemispherectomy, IGE, Patient, RCT

“The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.

Key Points: 
  • “The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We look forward to collaborating with the many healthcare providers, scientists, and others from all over the world who are gathering in Orlando to promote better outcomes for people with epilepsy.
  • We will host various presentations and events highlighting our RNS System and look forward to engaging with the broader scientific community in the epilepsy field.”
    Over 50 original scientific presentations and posters regarding the RNS System will be presented throughout the meeting, as well as a number of general meeting sessions that include how the RNS System provides an important therapy option for the treatment of drug resistant epilepsy.
  • These presentations, posters, and events involve key opinion leaders as well as early career scientists and clinicians, all of whom aim to improve the lives of patients living with drug-resistant epilepsy.